Genetically engineered Newcastle disease virus for malignant melanoma therapy - Wikidata - awgldk - TriplyDB

Genetically engineered Newcastle disease virus for malignant melanoma therapy

Genetically engineered Newcastle disease virus for malignant melanoma therapy

http://www.wikidata.org/entity/Q24597831

about

Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma Trial Watch:: Oncolytic viruses for cancer therapy Trial Watch-Oncolytic viruses and cancer therapy Experimental infection of mice with avian paramyxovirus serotypes 1 to 9.Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.Oncolytic viruses: From bench to bedside with a focus on safety.Inhibition of Pseudomonas aeruginosa with a recombinant RNA-based viral vector expressing human β-defensin 4.Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models Oncolysis by paramyxoviruses: preclinical and clinical studies.Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.The hemagglutinin-neuramidinase protein of Newcastle disease virus upregulates expression of the TRAIL gene in murine natural killer cells through the activation of Syk and NF-κB Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes Trial watch: Oncolytic viruses for cancer therapy Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model.New perspectives in cancer virotherapy: bringing the immune system into play.Use of attenuated paramyxoviruses for cancer therapy.Newcastle disease virus: a promising agent for tumour immunotherapy.Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.Oncolytic Immunotherapy for Treatment of Cancer.Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.Antineoplastic activity of Newcastle disease virus strain D90 in oral squamous cell carcinoma.Therapeutic potential of oncolytic Newcastle disease virus: a critical review.Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection.Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.Glycoprotein interactions in paramyxovirus fusion.Molecular characterization of an apoptotic strain of Newcastle disease virus isolated from an outbreak in India.Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer Optimizing the Targeting of Mouse Parvovirus 1 to Murine Melanoma Selects for Recombinant Genomes and Novel Mutations in the Viral Capsid Gene.Combination therapy of hTERTR and FAM96A for hepatocellular carcinoma through enhancing apoptosis sensitivity.PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway.Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer.Recombinant adenovirus expressing a dendritic cell-targeted melanoma surface antigen for tumor-specific immunotherapy in melanoma mice model.

P2860

Q24602706-D3618166-1935-4BF8-9D12-86C4451F0B51 Q24628144-F1BCF21A-0028-44CA-A6D7-BB964B940698 Q27021951-FE677F50-7D4A-411D-9F56-32E2661B09E6 Q28072347-E487398D-2DFE-4329-ABDF-0F4B3346104B Q33828508-FA4061F1-1300-4CD2-86C9-8388ACBCBB2A Q34028464-B7E64676-35FB-4FB2-9056-6E6C5C846917 Q34044071-7828019E-7CFB-48C0-8EB7-D87B5CA5C101 Q34304129-9B16C389-FFAD-4F60-9686-58704947FF0F Q35050645-F735BC42-5B22-44E5-A8F0-3513338DDBE1 Q35587389-19B2731E-5A5D-4D15-90E2-A60F1BB89A2E Q35861933-02727F24-7E9A-4313-8949-B822E4310E84 Q35861936-386956FF-5A83-4013-A066-EB1FF80A8C85 Q36405474-F5A567A4-96D1-4F9B-A927-D403DAD7EB3E Q36911654-F578A52B-F8A1-4911-BC32-6CF2562E14C8 Q37028023-FAB19757-8321-47F6-BB3B-019EAF8A24E0 Q37133496-65FF6F15-E350-46D6-98AA-4F11D72E668E Q37773253-12A7DD0E-E394-4221-BAB0-D9A8A0754989 Q37810599-55DCFC2B-DFBB-4553-BC5B-D311F5ABAC3E Q37972664-0AA04739-C5A3-4215-B63B-30431C888547 Q37990940-351A6926-DC47-4A77-AC83-2336B896973F Q38848223-7FB8454D-26E7-4183-8B73-72F04FE47E23 Q38860227-8070115B-ECE8-44DC-9970-39BEA85B1CD9 Q38886736-1A45BEA6-B9D5-4595-B71C-0FC4C7E82316 Q38924554-6F9CDBB9-F85E-4CB0-8DE2-670F894E77AE Q39037822-24A61CB0-7054-4CA6-88BF-45C888CC1BE8 Q39741135-1E023272-B308-44DC-B064-757903046E9C Q39900113-44E70B37-CA88-44CD-AA53-B082843F9BE3 Q41505946-9BC41EDC-BA7F-4F61-B0E6-85DF736CAD9A Q41699675-BD6AAF11-1BD1-4E2C-8BD4-5F92C3804A1D Q47547580-AC2C361F-7096-4598-9888-994F8FC1206E Q49215955-C625D4C9-4838-4B12-8402-FBD89B0FEBCA Q52674215-672C3E71-45AC-48AA-A7BC-1A2D0FC3C9B1 Q52686341-F49CD5A3-77C3-49D1-8E2F-9236D2EBF18E Q54219825-B3006766-9770-4A5F-A016-22E3255691FE Q54967512-535824BC-9602-44CC-90CB-1F150B0A4E76 Q55090825-B827D32F-4294-458D-88D0-69B46FC69ED3

P2860

Genetically engineered Newcastle disease virus for malignant melanoma therapy

http://www.wikidata.org/entity/Q24597831

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Genetically engineered Newcastle disease virus for malignant melanoma therapy

@ast

Genetically engineered Newcastle disease virus for malignant melanoma therapy

@en

Genetically engineered Newcastle disease virus for malignant melanoma therapy

@nl

type

label

Genetically engineered Newcastle disease virus for malignant melanoma therapy

@ast

Genetically engineered Newcastle disease virus for malignant melanoma therapy

@en

Genetically engineered Newcastle disease virus for malignant melanoma therapy

@nl

prefLabel

Genetically engineered Newcastle disease virus for malignant melanoma therapy

@ast

Genetically engineered Newcastle disease virus for malignant melanoma therapy

@en

Genetically engineered Newcastle disease virus for malignant melanoma therapy

@nl

P1433

Q24597831-E68C68DC-0DBF-4634-91E7-A1B81D415E9E

P1476

Q24597831-8169374B-80E0-49AF-8AF1-AEDE102A210E

P2093

Q24597831-3058AABD-16E2-4D61-AABC-5C4A25397453

Q24597831-3195D324-1216-471A-9436-27F76D5153F1

Q24597831-472BADCB-9167-4B66-A5EF-258464DE34F9

Q24597831-B2974CAD-F43A-4C61-B188-762EB0ECF758

P2860

Q24597831-01D34232-92E9-48D4-8CBA-6F09DAFBDC33

Q24597831-03621EB2-1EBC-4FF9-983A-0C66F7A4C6D3

Q24597831-0CDEB9D3-2D45-4F56-93CC-8E45C5EE5667

Q24597831-11BFDCD8-C6DF-4348-B7B4-22895C1A4662

Q24597831-19F379D3-1E8F-4D82-A178-2ACC909C0F00

Q24597831-20309184-D25B-4021-8AB8-B631F9B85BBB

Q24597831-2431FD13-ABB5-4A74-B216-CC1D5C14A121

Q24597831-2F76A546-1E6A-4CA0-9667-F990601B30C8

Q24597831-36B45852-1571-49AB-BAB5-0BF37180214C

Q24597831-37B7813C-74B8-40DF-9B6E-3D17A661A87C

P2888

Q24597831-34E5A00E-BE68-4590-B100-4E5D981CC3AE

P304

Q24597831-3D32489A-485E-48DF-9000-C37CA0301B2F

P31

Q24597831-8C7796EE-E7F4-4550-A6E8-A873BCD5987F

P3181

Q24597831-DC4A85C2-039F-45F1-B6AA-B150CBC164C1

P356

Q24597831-6A191DFE-0124-49E4-9FD7-D1F8A31B22ED

P407

Q24597831-8E81EE1C-4B92-40B2-A431-E42F7399EC8A

P433

Q24597831-7C00165A-E17A-499D-A982-50D6EA077B07

P478

Q24597831-EDE860B1-AAC6-4C5D-AE98-00A42D06317D

P50

Q24597831-FA31DA44-808F-41BC-B9BF-C978CFACDBFA

P577

Q24597831-41AE8F9D-D82F-44C2-A308-47E45EDE3A60

P5875

Q24597831-EEECB1D1-F2C3-4FCA-85F6-1C5FE3943603

P6179

Q24597831-4E15DB0F-1584-48D4-842C-D9450006DE5E

P698

Q24597831-3A5D4CB6-1C4C-4620-BB97-34A756C4C822

P921

Q24597831-68D6D7ED-B047-4511-B1B4-4E359B635BE6

P932

Q24597831-FD58FF71-05E3-4B98-A8E9-C91043C256E0

P3181

P356

P1433

P1476

Genetically engineered Newcastle disease virus for malignant melanoma therapy

@en

P2093

A Vigil

http://www.w3.org/2001/XMLSchema#string

D Zamarin

http://www.w3.org/2001/XMLSchema#string

K Kelly

http://www.w3.org/2001/XMLSchema#string

Y Fong

http://www.w3.org/2001/XMLSchema#string

P2860

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

Recombinant Newcastle disease virus as a vaccine vector for cancer therapy

p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.

Newcastle disease virus (NDV): brief history of its oncolytic strains.

Recombinant Newcastle disease virus as a vaccine vector

Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H).

The avian response to Newcastle disease virus.

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

P2888

P304

796-804

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4269008

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/GT.2009.14

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Adolfo García-Sastre

P577

2009-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24039822

http://www.w3.org/2001/XMLSchema#string

P6179

1020853701

http://www.w3.org/2001/XMLSchema#string

P698

19242529

http://www.w3.org/2001/XMLSchema#string

P921

P932

2882235

http://www.w3.org/2001/XMLSchema#string